Tumor Ablation Market Size, Share & Trends Analysis Report By Technology (Radiofrequency Ablation, Microwave Ablation), By Treatment, By Application, By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global tumor ablation market size was valued at USD 1.14 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 13.5% from 2022 to 2030. The rising prevalence of cancer and the high demand for safer therapeutic options are major factors contributing to the growth of the market. According to the WHO, it is projected that around 10-11 million cancer cases will be diagnosed each year globally by 2030. The number of new cancer cases is expected to increase by more than 80% in low-income countries compared to half the rate in high-income countries (40%) from 2008 to 2030. Lucrative growth potential in currently available therapeutic options and high demand for minimally and non-invasive therapies are the factors expected to drive the market in the upcoming years.

Increasing inclination of surgeons and patients toward minimally invasive procedures owing to the benefits such as speedy recovery, patient comfort, and reduced turnaround time are the factors expected to drive the demand for advanced tumor ablation techniques over the forecast period. Advanced tumor ablation procedures are generally performed on an outpatient basis and do not require any hospital admission compared with conventional therapies, thereby significantly reducing the total healthcare cost. The ablative surgeries are the preferred therapy for tumors of smaller sizes. Thus, its procedural volume is indirectly dependent on the yearly cancer screening rates. The market was significantly impacted in 2020 as the number of newly diagnosed cancer cases significantly dropped during COVID owing to fewer screening initiatives undertaken by concerned authorities.

According to a report by the Our World in Data (OWD), a project by Global Change Data Lab, over 70% of cancer cases occur in people aged over 50 in 2017. The number is expected to increase proportionally with the rising geriatric population. The aging population comprises the main target population for noninvasive ablation techniques as the body’s biological functions get compromised with aging. Therefore, the rapidly increasing aging population is expected to boost the demand for tumor ablation techniques during the forecast period.

Technological advancements to enhance accuracy, portability, and cost-effectiveness are the factors compelling market players to constantly improve and launch advanced devices. Image-guided equipment, HIFU, and cryoablation are major examples of these technological advancements. Usage of the cooled radiofrequency denervation technique with internally cooled radiofrequency probes to enlarge the size of the lesion is one of the emerging techniques that is anticipated to play a significant role in market expansion. This technique enables complete denervation of the sacroiliac joint, which helps in pain management.

Technology Insights

The radiofrequency tumor ablation technology segment held the largest revenue share of over 35.0% in 2021. The dominance can be attributed to its advantages such as specificity and efficiency in solid tumor ablation procedures in kidneys and liver. Additionally, radiofrequency ablation can be used to treat multiple tumors at the same time, thus improving procedural efficiency with the use of multiple electrodes placed at different sites. This is expected to boost the adoption rate of advanced tumor ablation techniques.

The success rate of radiofrequency/microwave ablation technology in eliminating small liver tumors is estimated to be greater than 85%. According to the NCBI report, recurrence of tumors in patients opting for surgical resection ranged from 30% to 70%. On the other hand, tumor recurrence is very low (0.7-8%) in cases of radiofrequency ablation for similar tumors. The advantages of radiofrequency techniques to successfully treat tumors at early stages are expected to drive the market during the forecast period.

Microwave ablation technology is anticipated to witness remunerative growth over the forecast period. The energy of the microwave (MW) ablation device is propagating an electromagnetic field, unlike the electric current in aradiofrequency ablation device. This improves the application of microwave ablation technology in tissue with low electrical conductance such as bones and lungs. Major benefits of this technology include larger tumor ablation volume, consistency in high temperature, low ablation pain, and optimal heating of the cystic mass. These benefits are anticipated to support the growth of this segment. Furthermore, minimum procedure time (5-10 minutes), improved efficacy with minimal complications, and reduced hospital stay are expected to drive the segment.

Application insights

Liver cancer dominated the market in 2021 with a revenue share of over 20.0%. This can be attributed to the rising incidence of bile duct cancer as well as primary liver cancer. Based on application, the market is segmented into kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer, and others. The others segment includes various types of cancer such as bone metastasis and ENT cancer. The availability of advanced methods and increasing cancer prevalence are anticipated to facilitate market growth.

Renal or kidney cancer is anticipated to witness lucrative growth during the forecast period. Radiofrequency and microwave ablation technology are effective in the treatment of renal tumors. Patients having solitary kidneys, tumor size less than 4cm, and a slow post-surgical recovery rate are prospects for ablation of kidney tumors. According to the American Cancer Society’s estimates for 2022, 79,000 new cases of renal cancer will be diagnosed. Additionally, with the increasing use of medical imaging, the number of diagnosed cases is expected to increase, thereby driving the demand for treatment procedures during the forecast period.

The market for lung tumor ablation is anticipated to grow at a rapid pace during the forecast period. This can be attributed to the increasing incidence of the disease. For instance, in 2018, lung cancer accounted for nearly 11.6% of total new cancer cases across the globe, meanwhile, Non-Small Cell Lung Cancer (NSCLC) accounted for 85% of all lung cancer cases. Radiofrequency ablation is widely used for the treatment of NSCL and is thereby anticipated to propel market growth.

Treatment Insights

The surgical ablation segment held the largest revenue share of over 35.0% in 2021. Increased prevalence of liver and breast cancer and the unavailability of advanced tumor ablation techniques for these particular organs are the factors estimated to fuel the segment growth. The percutaneous ablation segment is expected to witness lucrative growth over the forecast period. These procedures offer faster recovery, minimal scarring, and increased safety. In addition, factors such as quick surgery time, patient comfort, and cost-efficiency are anticipated to further boost the segment demand. However, higher complications associated with the system are anticipated to limit its growth, especially in the hospitals lacking skilled professionals.

According to the NCBI report, percutaneous ablations are not feasible in about 25-55% of patients due to unfavorable tumor locations. The tumor recurrence rate is higher in percutaneous ablation due to insufficient ablation of the tumors located deep inside the tissue. Additionally, percutaneous ablation is contraindicated in treating lesions that are very adjacent to the gastrointestinal tract, gall bladder, bile duct, and heart due to the high risk of tumor recurrence. Therefore, in such a case, laparoscopic ablation is efficient in providing long-term outcomes with simultaneously retaining minimal invasiveness. This is expected to boost the laparoscopic ablation segment growth during the forecast period.

Regional Insights

北美主导市场的收入share of over 30.0% in 2021. Major factors contributing to the growth of this region include government support for quality healthcare, high purchasing power parity, the availability of reimbursements, and the increasing prevalence of cancer. For instance, in the U.S., the Patient Protection and Affordable Care Act (PPACA) promotes the quality and affordability of health care through health coverage policies, which reduces the cost of healthcare for individuals and the government. In addition, the precision medicine initiative in formulating tailored strategies for unique characteristics of diseases is a key growth factor. Hence, such government initiatives are anticipated to improve the overall healthcare system, thus boosting market growth.

Europe held a considerable revenue share in 2021. A greater extent of public funding in Europe’s healthcare system contributed to this growth. Moreover, the growing geriatric population, coupled with government support to control cancer, is estimated to boost the market growth in this region. For instance, the European Cancer Observatory aims to create awareness about cancer, early diagnostic techniques, and advanced minimally invasive therapeutic options.

Asia Pacific is expected to register the fastest growth rate during the forecast period. Expanding patient population and the growing presence of major healthcare providers in rapidly developing economies such as India and China open growth opportunities. In addition, with government assistance, healthcare utilization in Asia Pacific is improving. For instance, the Indian government provides financial assistance for poor patients suffering from cancer under the Health Minister Cancer Patient Fund (HMCPF) scheme. This is anticipated to fuel the demand for tumor ablation devices in this region over the forecast period.

Key Companies & Market Share Insights

Key companies are significantly investing in R&D to develop minimally invasive and innovative tumor ablative solutions with the intent to acquire a large market share. For instance, in August 2019, Boston Scientific Corporation received Health Canada approval for its advanced cryoablation system named ICEfx™. The device has a smaller footprint, is portable, and is a powerful alternative to the existing cryoablation systems.

The market players have adopted various strategic initiatives such as product launches, partnerships, mergers, and acquisitions to sustain their position in the market. In March 2018, Auris Health announced a partnership with Ethicon to develop robotically-assisted bronchoscopy tumor ablative systems. Some prominent players in the global tumor ablation market include:

• Angiodynamics (Covidien)

• Boston Scientific Corporation

• Medtronic Plc

• Ethicon, Inc.

• Galil Medical Inc.

• Misonix Inc.

• HealthTronics

• Mermaid Medical

• Theraclion

• Chongqing Haifu Medical Technology Co., Ltd.

• HS Hospital Service S.P.A

• EDAP TMS S.A.

Tumor Ablation Market Report Scope

Report Attribute	Details
Market size value in 2022	USD 1.48 billion
Revenue forecast in 2030	USD 4.08 billion
Growth Rate	CAGR of 13.5% from 2022 to 2030
Base year for estimation	2021
Historical data	2017 - 2020
Forecast period	2022 - 2030
Quantitative units	Revenue in USD million and CAGR from 2022 to 2030
Report coverage	Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered	Technology, treatment, application, region
Regional scope	北美;欧洲;亚太地区;拉丁美洲; MEA
数ry scope	U.S.; Canada; U.K.; Germany; France; Italy; Spain; Russia; Netherland; Switzerland; Belgium; Hungary; China; India; Japan; Thailand; South Korea; Taiwan; Singapore; Malaysia; Indonesia; Philippines; Mexico; Brazil; Colombia; Argentina; Chile; South Africa; Saudi Arabia; UAE; Turkey; Israel
Key companies profiled	Angiodynamics (Covidien); Ethicon, Inc.; Boston Scientific Corporation; Medtronic Plc.; Galil Medical Inc.; Misonix Inc.; HealthTronics; Mermaid Medical; Ethicon, Inc.; Theraclion; Chongqing Haifu Medical Technology Co., Ltd.; HS Hospital Service S.P.A; EDAP TMS S.A; SonaCare Medical; Neuwave Medical Inc.
Customization scope	Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs.Explore purchase options

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2017 to 2030. For this study, Grand View Research has segmented the global tumor ablation market report based on technology, treatment, application, and region:

• Technology Outlook (Revenue, USD Million, 2017 - 2030)

  • Radiofrequency Ablation

  • Microwave Ablation

  • Cryoablation

  • Irreversible Electroporation Ablation

  • Other Ablation Technologies

• Treatment Outlook (Revenue, USD Million, 2017 - 2030)

  • Surgical Ablation

    • Kidney Cancer

    • Liver Cancer

    • Breast Cancer

    • Lung Cancer

    • Prostate Cancer

    • Other Cancers

  • Laparoscopic Ablation

    • Kidney Cancer

    • Liver Cancer

    • Breast Cancer

    • Lung Cancer

    • Prostate Cancer

    • Other Cancers

  • Percutaneous Ablation

    • Kidney Cancer

    • Liver Cancer

    • Breast Cancer

    • Lung Cancer

    • Prostate Cancer

    • Other Cancers

• Application Outlook (Revenue, USD Million, 2017 - 2030)

  • Kidney Cancer

  • Liver Cancer

  • Breast Cancer

  • Lung Cancer

  • Prostate Cancer

  • Other Cancer

• Regional Outlook (Revenue, USD Million, 2017 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

    • Russia

    • Netherland

    • Switzerland

    • Belgium

    • Hungary

  • Asia Pacific

    • China

    • Japan

    • India

    • Thailand

    • South Korea

    • Taiwan

    • Malaysia

    • Singapore

    • Indonesia

    • Philippines

  • 拉丁美洲

    • Brazil

    • Mexico

    • Argentina

    • Colombia

    • Chile

  • Middle East & Africa

    • 南非

    • Saudi Arabia

    • UAE

    • Turkey

    • Israel